[go: up one dir, main page]

ES2148251T3 - Metodos para detectar selectivamente anticuerpos anticitoplasma de neutrofilos perinucleares de la colitis ulcerosa o colangitis esclerosante primaria. - Google Patents

Metodos para detectar selectivamente anticuerpos anticitoplasma de neutrofilos perinucleares de la colitis ulcerosa o colangitis esclerosante primaria.

Info

Publication number
ES2148251T3
ES2148251T3 ES94103727T ES94103727T ES2148251T3 ES 2148251 T3 ES2148251 T3 ES 2148251T3 ES 94103727 T ES94103727 T ES 94103727T ES 94103727 T ES94103727 T ES 94103727T ES 2148251 T3 ES2148251 T3 ES 2148251T3
Authority
ES
Spain
Prior art keywords
colangitis
primary
perinuclear
methods
ulcerous colitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94103727T
Other languages
English (en)
Inventor
Stephan R M D Targan
Alda Vidrich Ph D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ES2148251T3 publication Critical patent/ES2148251T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125—Digestion or removing interfering materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL INVENTO ESTA DIRIGIDO A METODOS Y EQUIPOS PARA DETECTAR Y MEDIR LA PRESENCIA O AUSENCIA DE AUTOANTICUERPOS PERINUCLEARES ANTI-NEUTROFIL CITOPLASMICOS DE COLITIS ULCEROSA O COLANGITIS PRIMARIA ESCLEROSANTE. LOS METODOS Y EQUIPOS DEL PRESENTE INVENTO PROPORCIONAN MEDIOS SEGUROS Y FIABLES PARA EL DIAGNOSTICO DE COLITIS ULCEROSA Y COLANGITIS PRIMARIA ESCLEROSANTE. TAMBIEN SE PREVEN LOS ANTIGENOS REACCIONAN CON AUTOANTICUERPOS PERINUCLEARES ANTI-NEUTROFIL CITOPLASMICOS DE COLITIS ULCEROSA O COLANGITIS PRIMARIA ESCLEROSANTE.
ES94103727T 1993-03-10 1994-03-10 Metodos para detectar selectivamente anticuerpos anticitoplasma de neutrofilos perinucleares de la colitis ulcerosa o colangitis esclerosante primaria. Expired - Lifetime ES2148251T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2878493A 1993-03-10 1993-03-10

Publications (1)

Publication Number Publication Date
ES2148251T3 true ES2148251T3 (es) 2000-10-16

Family

ID=21845400

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94103727T Expired - Lifetime ES2148251T3 (es) 1993-03-10 1994-03-10 Metodos para detectar selectivamente anticuerpos anticitoplasma de neutrofilos perinucleares de la colitis ulcerosa o colangitis esclerosante primaria.

Country Status (6)

Country Link
US (1) US5750355A (es)
EP (1) EP0615129B1 (es)
AT (1) ATE193601T1 (es)
DE (1) DE69424700T2 (es)
DK (1) DK0615129T3 (es)
ES (1) ES2148251T3 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6630947B1 (en) * 1996-04-10 2003-10-07 The United States Of America As Represented By The Secretary Of The Navy Method for examining subsurface environments
EP0959900B1 (en) * 1996-04-12 2008-06-11 The Regents Of The University Of California Diagnosis of ulcerative colitis, and clinical subtypes thereof, using histone h1
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6183951B1 (en) * 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
WO2004022713A2 (en) 2002-09-05 2004-03-18 Techlab, Inc. Method for distinguishing ulcerative colitis from crohn's disease by detecting the presence of fecal anti-neutrophil cytoplasmic antibodies (anca)
US20040076960A1 (en) * 2002-10-18 2004-04-22 Taylor Kent D. Methods of using a NOD2/CARD15 haplotype to diagnose Crohn's disease
CA2502976C (en) 2002-10-25 2012-05-22 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
EP1819827B1 (en) * 2004-12-08 2010-08-11 Cedars-Sinai Medical Center Methods for diagnosis of crohn's disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
CN1316250C (zh) * 2005-05-01 2007-05-16 李小峰 中性粒细胞抗原底片的制备方法
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8685741B1 (en) 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20100129838A1 (en) * 2008-11-11 2010-05-27 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010120814A1 (en) * 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
EP2778685B1 (en) 2009-06-25 2017-04-26 Nestec S.A. Methods for diagnosing irritable bowel syndrome
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
CN103299190B (zh) 2010-10-18 2017-02-15 雀巢产品技术援助有限公司 确定抗药物抗体同种型的方法
CA2839792A1 (en) 2011-05-10 2012-11-15 Nestec S.A. Methods of disease activity profiling for personalized therapy management
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
AU2012325798B2 (en) 2011-10-21 2015-11-26 Société des Produits Nestlé S.A. Methods for improving inflammatory bowel disease diagnosis
EP3217179B9 (en) 2012-10-05 2020-06-10 Prometheus Biosciences, Inc. Methods for predicting and monitoring mucosal healing
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3077818B1 (en) 2013-12-03 2020-02-05 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
EP3077538A1 (en) 2013-12-03 2016-10-12 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
JP2018504584A (ja) 2014-12-02 2018-02-15 ネステク ソシエテ アノニム 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CA3078779A1 (en) 2017-10-10 2019-04-18 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
CN111024468A (zh) * 2019-12-20 2020-04-17 天津金域医学检验实验室有限公司 一种呼吸道病原体免疫荧光检测中样本的处理方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487830A (en) * 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
US5292667A (en) * 1988-06-29 1994-03-08 The General Hospital Corporation Detection and treatment of ulcerative colitis
WO1992002819A2 (en) * 1990-08-10 1992-02-20 The Regents Of The University Of California Assay for ulcerative colitis and primary sclerosing cholangitis
US5238813A (en) * 1990-12-18 1993-08-24 Washington University Diagnostic method for nephritis
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using

Also Published As

Publication number Publication date
DE69424700T2 (de) 2000-11-09
EP0615129A3 (en) 1995-07-05
DK0615129T3 (da) 2000-08-07
EP0615129B1 (en) 2000-05-31
ATE193601T1 (de) 2000-06-15
DE69424700D1 (de) 2000-07-06
US5750355A (en) 1998-05-12
EP0615129A2 (en) 1994-09-14

Similar Documents

Publication Publication Date Title
ES2148251T3 (es) Metodos para detectar selectivamente anticuerpos anticitoplasma de neutrofilos perinucleares de la colitis ulcerosa o colangitis esclerosante primaria.
FR2708751B1 (fr) Procédé et dispositif pour détecter la présence d'un objet, comportant un matériau donné, non accessible à la vue.
NO975688L (no) Differensialanalyse for ulcerös kolitt, primær skleroserende cholangitt og type 1 autoimmunhepatitt
DE50005467D1 (de) Streulichtbrandmelder
ES2182366T3 (es) Alarma de incendio.
ES8302251A1 (es) Un dispositivo perceptor del estado de una valvula
NO864648D0 (no) Anordning for deteksjon og lokalisering av noeytrale partikler, samt anvendelse av denne anordning.
JPS5681417A (en) Inspecting device for shape of columnar body
ES2114207T3 (es) Dispositivo y procedimiento de medida sin contacto de revestimientos internos de tuberias de fundicion.
DE59308231D1 (de) Vakuum-lecksuchgerät für die testgaslecksuche mit leichten gasen
ES2126916T3 (es) Dispositivo de deteccion de incendio con correccion de parametros perturbadores.
JPS52151047A (en) Detecting apparatus of inside diameter, outside diameter and roundness of long length objects
FR2510741B1 (fr) Dispositif de detection du diametre exterieur d'une bande enroulee en rouleau
JPS56158977A (en) Presence detector
ES2039563T3 (es) Dispositivo para detectar un medio magnetico.
JPS5524225A (en) Information detecting system by optical transmitter
SE9100804L (sv) Anordning foer undersoekning av icke-metalliska foeremaal foer att upptaecka och lokalisera daeri befintliga element med avvikande densitet
JPS57173771A (en) Position detecting system of moving body
JPS5322759A (en) Thickness de tector of plate form objects
JPS53123116A (en) Tape running direction discriminating system
JPS5315878A (en) Leak tester
JPS52142193A (en) Natrium leaked position detecting device
JPS5240164A (en) Metal body detector
IT1119018B (it) Dispositivo rivelatore della presenza o assenza di un corpo
JPS5242141A (en) Device for automatic detection of outside diameter of round pipe

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 615129

Country of ref document: ES